Oxypurinol (BioDeep_00000003006)

 

Secondary id: BioDeep_00000400350

natural product human metabolite PANOMIX_OTCML-2023 Endogenous blood metabolite


代谢物信息卡片


1H,2H,4H,5H,6H-pyrazolo[3,4-d]pyrimidine-4,6-dione

化学式: C5H4N4O2 (152.0334)
中文名称: 1H-吡唑并[3,4-d]嘧啶-4,6(2H,5H)-二酮, 奥昔嘌醇, 羟基嘌呤, 氧嘌呤醇
谱图信息: 最多检出来源 Homo sapiens(blood) 11.42%

分子结构信息

SMILES: C1=C2C(=NC(=O)NC2=O)NN1
InChI: InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11)

描述信息

Oxipurinol is a xanthine oxidase inhibitor. Oxipurinol is potentially used for treatment of congestive heart failure. PMID: 15139781.
Oxipurinol is a xanthine oxidase inhibitor. Oxipurinol is potentially used for treatment of congestive heart failure.
C471 - Enzyme Inhibitor > C1637 - Xanthine Oxidase Inhibitor
D004791 - Enzyme Inhibitors
CONFIDENCE standard compound; INTERNAL_ID 864; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 855; ORIGINAL_PRECURSOR_SCAN_NO 853
CONFIDENCE standard compound; INTERNAL_ID 864; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 883; ORIGINAL_PRECURSOR_SCAN_NO 881
CONFIDENCE standard compound; INTERNAL_ID 864; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 893; ORIGINAL_PRECURSOR_SCAN_NO 892
CONFIDENCE standard compound; INTERNAL_ID 864; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 861; ORIGINAL_PRECURSOR_SCAN_NO 860
CONFIDENCE standard compound; INTERNAL_ID 864; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 894; ORIGINAL_PRECURSOR_SCAN_NO 892
Acquisition and generation of the data is financially supported in part by CREST/JST.
Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxipurinol can be used to regulate blood urate levels and treat gout[1].

同义名列表

12 个代谢物同义名

1H,2H,4H,5H,6H-pyrazolo[3,4-d]pyrimidine-4,6-dione; 1H-Pyrazolo[3,4-d]pyrimidine-4,6(2H,5H)-dione; 4,6-Dihydroxypyrazolo[3,4-D]pyrimidine; 1H-Pyrazolo[3,4-D]pyrimidin-4,6-diol; 1H,3H,9H-Alloxanthine; Oxoallopurinol; Alloxanthine; Oxipurinol; Oxypurinol; 1,2-dihydropyrazolo[3,4-d]pyrimidine-4,6-dione; Alloxanthine; Oxypurinol



数据库引用编号

37 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

21 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 8 ADA, ALB, CA1, CAT, ELANE, NOS2, NOS3, XDH
Peripheral membrane protein 1 ADA
Endosome membrane 1 HLA-B
Endoplasmic reticulum membrane 2 HLA-B, HMOX1
Mitochondrion membrane 1 ABCG2
Nucleus 5 ALB, HMOX1, MPO, NOS2, NOS3
cytosol 9 ADA, ALB, CA1, CAT, ELANE, HMOX1, NOS2, NOS3, XDH
mitochondrial membrane 1 ABCG2
phagocytic vesicle 1 ELANE
centrosome 1 ALB
nucleoplasm 5 ABCG2, HMOX1, MPO, NOS2, NOS3
Cell membrane 4 ABCG2, ADA, HLA-B, TNF
Cytoplasmic side 1 HMOX1
Early endosome membrane 1 HLA-B
Multi-pass membrane protein 4 ABCG2, SLC22A12, SLC22A9, SLC2A9
cell junction 1 ADA
cell surface 4 ADA, ELANE, HLA-B, TNF
Golgi apparatus 3 ALB, HLA-B, NOS3
Golgi membrane 2 HLA-B, NOS3
lysosomal membrane 1 HLA-B
neuronal cell body 1 TNF
Cytoplasm, cytosol 1 NOS2
Lysosome 2 ADA, MPO
plasma membrane 9 ABCG2, ADA, HLA-B, NOS2, NOS3, REN, SLC22A12, SLC2A9, TNF
Membrane 8 ABCG2, ADA, CAT, HLA-B, HMOX1, REN, SLC22A12, SLC2A9
apical plasma membrane 3 ABCG2, SLC22A12, SLC2A9
basolateral plasma membrane 2 SLC22A9, SLC2A9
caveola 1 NOS3
extracellular exosome 8 ALB, CA1, CAT, ELANE, HLA-B, MPO, SLC22A12, SOD2
Lysosome membrane 1 HLA-B
endoplasmic reticulum 3 ALB, HLA-B, HMOX1
extracellular space 9 ALB, ELANE, GNLY, HLA-B, HMOX1, MPO, REN, TNF, XDH
perinuclear region of cytoplasm 3 HMOX1, NOS2, NOS3
mitochondrion 2 CAT, SOD2
protein-containing complex 2 ALB, CAT
intracellular membrane-bounded organelle 2 CAT, MPO
Single-pass type I membrane protein 1 HLA-B
Secreted 2 ALB, REN
extracellular region 7 ALB, CAT, ELANE, GNLY, MPO, REN, TNF
Single-pass membrane protein 1 HLA-B
mitochondrial outer membrane 1 HMOX1
Mitochondrion matrix 1 SOD2
mitochondrial matrix 2 CAT, SOD2
Extracellular side 1 ADA
Cytoplasmic vesicle lumen 1 ADA
anchoring junction 2 ADA, ALB
external side of plasma membrane 3 ADA, HLA-B, TNF
Cytoplasm, P-body 2 NOS2, NOS3
P-body 2 NOS2, NOS3
apical part of cell 1 REN
recycling endosome 1 TNF
Single-pass type II membrane protein 1 TNF
Apical cell membrane 3 ABCG2, SLC22A12, SLC2A9
Cytoplasm, perinuclear region 1 NOS2
Membrane raft 2 ABCG2, TNF
focal adhesion 1 CAT
mitochondrial nucleoid 1 SOD2
Peroxisome 3 CAT, NOS2, XDH
sarcoplasmic reticulum 1 XDH
Peroxisome matrix 1 CAT
peroxisomal matrix 2 CAT, NOS2
peroxisomal membrane 1 CAT
collagen-containing extracellular matrix 1 ELANE
secretory granule 2 ELANE, MPO
ciliary basal body 1 ALB
phagocytic cup 1 TNF
phagocytic vesicle membrane 1 HLA-B
cytoskeleton 1 NOS3
centriole 1 ALB
brush border membrane 2 ABCG2, SLC22A12
spindle pole 1 ALB
blood microparticle 1 ALB
Basolateral cell membrane 2 SLC22A9, SLC2A9
[Isoform 2]: Cell membrane 1 SLC2A9
Recycling endosome membrane 1 HLA-B
Cytoplasm, Stress granule 1 NOS3
cytoplasmic stress granule 1 NOS3
azurophil granule 1 MPO
ficolin-1-rich granule lumen 1 CAT
secretory granule lumen 1 CAT
secretory granule membrane 1 HLA-B
endoplasmic reticulum lumen 1 ALB
transcription repressor complex 1 ELANE
platelet alpha granule lumen 1 ALB
specific granule lumen 1 ELANE
endocytic vesicle membrane 1 NOS3
azurophil granule lumen 2 ELANE, MPO
Single-pass type IV membrane protein 1 HMOX1
ER to Golgi transport vesicle membrane 1 HLA-B
phagocytic vesicle lumen 2 GNLY, MPO
external side of apical plasma membrane 1 ABCG2
lumenal side of endoplasmic reticulum membrane 1 HLA-B
[Isoform 1]: Cell membrane 1 SLC2A9
Cytoplasmic vesicle, phagosome 1 ELANE
[Tumor necrosis factor, soluble form]: Secreted 1 TNF
MHC class I protein complex 1 HLA-B
MHC class II protein complex 1 HLA-B
cortical cytoskeleton 1 NOS2
catalase complex 1 CAT
ciliary transition fiber 1 ALB
[C-domain 2]: Secreted 1 TNF
[Tumor necrosis factor, membrane form]: Membrane 1 TNF
[C-domain 1]: Secreted 1 TNF


文献列表

  • Bianca Vora, Deanna J Brackman, Ling Zou, Maria Garcia-Cremades, Marina Sirota, Radojka M Savic, Kathleen M Giacomini. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. Clinical and translational science. 2021 07; 14(4):1431-1443. doi: 10.1111/cts.12992. [PMID: 33931953]
  • Lisa K Stamp, Peter T Chapman. Allopurinol hypersensitivity: Pathogenesis and prevention. Best practice & research. Clinical rheumatology. 2020 08; 34(4):101501. doi: 10.1016/j.berh.2020.101501. [PMID: 32265121]
  • Ana Leonor P C Godoy, Clauceane de Jesus, Rafaela S Gonçalves, Francine Johansson Azeredo, Adriana Rocha, Maria P Marques, Vera L Lanchote, Daniela F Larangeira, Stella Maria Barrouin-Melo. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: Focus on veterinary clinical pharmacokinetics. Journal of pharmaceutical and biomedical analysis. 2020 Jun; 185(?):113204. doi: 10.1016/j.jpba.2020.113204. [PMID: 32126445]
  • Francisco J López-Iranzo, Ana M López-Rodas, Luis Franco, Gerardo López-Rodas. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine Release (Storm) Syndrome" Caused by SARS-CoV-2?. Current pharmaceutical design. 2020; 26(35):4515-4521. doi: 10.2174/1381612826666200811180232. [PMID: 32787748]
  • Lisa K Stamp, Peter T Chapman, Murray Barclay, Anne Horne, Christopher Frampton, Tony R Merriman, Daniel F B Wright, Jill Drake, Nicola Dalbeth. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration. Clinical and translational science. 2020 01; 13(1):110-115. doi: 10.1111/cts.12686. [PMID: 31444839]
  • Hiroshi Arakawa, Natsumi Amezawa, Tomomichi Katsuyama, Takeo Nakanishi, Ikumi Tamai. Uric acid analogue as a possible xenobiotic marker of uric acid transporter Urat1 in rats. Drug metabolism and pharmacokinetics. 2019 Apr; 34(2):155-158. doi: 10.1016/j.dmpk.2018.12.003. [PMID: 30826184]
  • Muzaffar Iqbal, Essam Ezzeldin, Rashed Naji Herqash, Ozair Alam. Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. PloS one. 2019; 14(3):e0213786. doi: 10.1371/journal.pone.0213786. [PMID: 30870504]
  • Dongmei Zhou, Lifang Sun, Mai Nguyen, Li- Tain Yeh, David M Wilson. The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS. Drug metabolism letters. 2019; 13(2):111-122. doi: 10.2174/1872312813666191015162634. [PMID: 31613735]
  • Angus Lindsay, Preston M McCourt, Peter Karachunski, Dawn A Lowe, James M Ervasti. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy. Free radical biology & medicine. 2018 12; 129(?):364-371. doi: 10.1016/j.freeradbiomed.2018.10.404. [PMID: 30312761]
  • Martin Kankam, Jesse Hall, Michael Gillen, Xiaojuan Yang, Zancong Shen, Caroline Lee, Sha Liu, Jeffrey N Miner, Susan Walker, Vicki Clauson, David Wilson, Mai Nguyen. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. Journal of clinical pharmacology. 2018 09; 58(9):1214-1222. doi: 10.1002/jcph.1119. [PMID: 29733447]
  • Makiko Nakamura, Kyoko Fujita, Yu Toyoda, Tappei Takada, Hiroshi Hasegawa, Kimiyoshi Ichida. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2. Drug metabolism and pharmacokinetics. 2018 Feb; 33(1):77-81. doi: 10.1016/j.dmpk.2017.11.002. [PMID: 29342419]
  • Lisa K Stamp, Tony Merriman, Christopher Frampton, Mei Zhang, Mary Wallace, Jeffrey N Miner, Nicola Dalbeth. Plasma oxypurinol as a measure of adherence in clinical trials. Annals of the rheumatic diseases. 2018 02; 77(2):313-314. doi: 10.1136/annrheumdis-2016-210661. [PMID: 28057666]
  • Diluk R W Kannangara, Garry G Graham, Daniel F B Wright, Sophie L Stocker, Ian Portek, Kevin D Pile, Murray L Barclay, Kenneth M Williams, Lisa K Stamp, Richard O Day. Individualising the dose of allopurinol in patients with gout. British journal of clinical pharmacology. 2017 Sep; 83(9):2015-2026. doi: 10.1111/bcp.13307. [PMID: 28417592]
  • Daniel Fb Wright, Matthew P Doogue, Murray L Barclay, Peter T Chapman, Nicholas B Cross, John H Irvine, Lisa K Stamp. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European journal of clinical pharmacology. 2017 Jan; 73(1):71-78. doi: 10.1007/s00228-016-2133-y. [PMID: 27683090]
  • Lisa K Stamp, Richard O Day, James Yun. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nature reviews. Rheumatology. 2016 Apr; 12(4):235-42. doi: 10.1038/nrrheum.2015.132. [PMID: 26416594]
  • Jun Fang, Hongzhuan Yin, Long Liao, Haibo Qin, Fumiko Ueda, Kyoko Uemura, Kanami Eguchi, Gahininath Y Bharate, Hiroshi Maeda. Water soluble PEG-conjugate of xanthine oxidase inhibitor, PEG-AHPP micelles, as a novel therapeutic for ROS related inflammatory bowel diseases. Journal of controlled release : official journal of the Controlled Release Society. 2016 Feb; 223(?):188-196. doi: 10.1016/j.jconrel.2015.12.049. [PMID: 26739550]
  • Daniel F B Wright, Stephen B Duffull, Tony R Merriman, Nicola Dalbeth, Murray L Barclay, Lisa K Stamp. Predicting allopurinol response in patients with gout. British journal of clinical pharmacology. 2016 Feb; 81(2):277-89. doi: 10.1111/bcp.12799. [PMID: 26451524]
  • Wen-Hung Chung, Wan-Chun Chang, Sophie L Stocker, Chiun-Gung Juo, Garry G Graham, Ming-Han H Lee, Kenneth M Williams, Ya-Chung Tian, Kuo-Chang Juan, Yeong-Jian Jan Wu, Chih-Hsun Yang, Chee-Jen Chang, Yu-Jr Lin, Richard O Day, Shuen-Iu Hung. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Annals of the rheumatic diseases. 2015 Dec; 74(12):2157-64. doi: 10.1136/annrheumdis-2014-205577. [PMID: 25115449]
  • Jan Funke, Carsten Prasse, Christian Lütke Eversloh, Thomas A Ternes. Oxypurinol - A novel marker for wastewater contamination of the aquatic environment. Water research. 2015 May; 74(?):257-65. doi: 10.1016/j.watres.2015.02.007. [PMID: 25753675]
  • Xia Liu, Xiao-Jia Ni, De-Wei Shang, Ming Zhang, Jin-Qing Hu, Chang Qiu, Fu-Tian Luo, Yu-Guan Wen. Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013 Dec; 941(?):10-6. doi: 10.1016/j.jchromb.2013.09.028. [PMID: 24184830]
  • Diluk R W Kannangara, Sheena N Ramasamy, John E Ray, Graham Jones, Garry G Graham, Kenneth M Williams, Richard O Day. An audit of a therapeutic drug monitoring service for allopurinol therapy. Therapeutic drug monitoring. 2013 Dec; 35(6):863-6. doi: 10.1097/ftd.0b013e318299920a. [PMID: 24263644]
  • P A Blaker, M Arenas-Hernandez, M A Smith, E A Shobowale-Bakre, L Fairbanks, P M Irving, J D Sanderson, A M Marinaki. Mechanism of allopurinol induced TPMT inhibition. Biochemical pharmacology. 2013 Aug; 86(4):539-47. doi: 10.1016/j.bcp.2013.06.002. [PMID: 23770457]
  • Daniel F B Wright, Lisa K Stamp, Tony R Merriman, Murray L Barclay, Stephen B Duffull, Nicholas H G Holford. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European journal of clinical pharmacology. 2013 Jul; 69(7):1411-21. doi: 10.1007/s00228-013-1478-8. [PMID: 23475133]
  • Jochen Springer, Anika Tschirner, Kai Hartman, Sandra Palus, Eva K Wirth, Silvia Busquets Ruis, Nadine Möller, Stephan von Haehling, Josep M Argiles, Josef Köhrle, Volker Adams, Stefan D Anker, Wolfram Doehner. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. International journal of cancer. 2012 Nov; 131(9):2187-96. doi: 10.1002/ijc.27494. [PMID: 22336965]
  • Lisa K Stamp, Murray L Barclay, John L O'Donnell, Mei Zhang, Jill Drake, Christopher Frampton, Peter T Chapman. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. Rheumatology (Oxford, England). 2012 Sep; 51(9):1670-6. doi: 10.1093/rheumatology/kes091. [PMID: 22539486]
  • Sophie L Stocker, Andrew J McLachlan, Radojka M Savic, Carl M Kirkpatrick, Garry G Graham, Kenneth M Williams, Richard O Day. The pharmacokinetics of oxypurinol in people with gout. British journal of clinical pharmacology. 2012 Sep; 74(3):477-89. doi: 10.1111/j.1365-2125.2012.04207.x. [PMID: 22300439]
  • Diluk R W Kannangara, Darren M Roberts, Timothy J Furlong, Garry G Graham, Kenneth M Williams, Richard O Day. Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease. British journal of clinical pharmacology. 2012 May; 73(5):828-9. doi: 10.1111/j.1365-2125.2011.04147.x. [PMID: 22098112]
  • Paolo Puddu, Giovanni M Puddu, Eleonora Cravero, Luca Vizioli, Antonio Muscari. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. Journal of cardiology. 2012 May; 59(3):235-42. doi: 10.1016/j.jjcc.2012.01.013. [PMID: 22398104]
  • Ramón Rodrigo. Prevention of postoperative atrial fibrillation: novel and safe strategy based on the modulation of the antioxidant system. Frontiers in physiology. 2012; 3(?):93. doi: 10.3389/fphys.2012.00093. [PMID: 22518106]
  • Mohammad M Hudaib, Khaled A Tawaha, Mohammad K Mohammad, Areej M Assaf, Ala Y Issa, Feras Q Alali, Talal A Aburjai, Yasser K Bustanji. Xanthine oxidase inhibitory activity of the methanolic extracts of selected Jordanian medicinal plants. Pharmacognosy magazine. 2011 Oct; 7(28):320-4. doi: 10.4103/0973-1296.90413. [PMID: 22262935]
  • Rodrigo Frezzatti, Paulo Flavio Silveira. Allopurinol reduces the lethality associated with acute renal failure induced by Crotalus durissus terrificus snake venom: comparison with probenecid. PLoS neglected tropical diseases. 2011 Sep; 5(9):e1312. doi: 10.1371/journal.pntd.0001312. [PMID: 21909449]
  • L K Stamp, M L Barclay, J L O'Donnell, M Zhang, J Drake, C Frampton, P T Chapman. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clinical pharmacology and therapeutics. 2011 Sep; 90(3):392-8. doi: 10.1038/clpt.2011.113. [PMID: 21796116]
  • Mahesh J Fuldeore, Aylin A Riedel, Victoria Zarotsky, Bhavik J Pandya, Omar Dabbous, Eswar Krishnan. Chronic kidney disease in gout in a managed care setting. BMC nephrology. 2011 Aug; 12(?):36. doi: 10.1186/1471-2369-12-36. [PMID: 21812963]
  • Daniel Y Ng, Sophie L Stocker, Garry G Graham, Kenneth M Williams, Richard O Day. Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers. European journal of clinical pharmacology. 2011 Jul; 67(7):709-13. doi: 10.1007/s00228-010-0963-6. [PMID: 21181139]
  • Christiane Funk, Meriem Alami, Tania Tibiletti, Beverley R Green. High light stress and the one-helix LHC-like proteins of the cryptophyte Guillardia theta. Biochimica et biophysica acta. 2011 Jul; 1807(7):841-6. doi: 10.1016/j.bbabio.2011.03.011. [PMID: 21459077]
  • M Kurajoh, T Ka, C Okuda, A Yamamoto, Z Tsutsumi, H Koyama, Y Moriwaki, T Yamamoto. Effects of bovine milk ingestion on urinary excretion of oxypurinol and uric acid. International journal of clinical pharmacology and therapeutics. 2011 Jun; 49(6):366-70. doi: 10.5414/cp201508. [PMID: 21612743]
  • Tatsuo Hosoya, Hosoya Tatsuo, Iwao Ohno, Ohno Iwao. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2011 Jun; 17(4 Suppl 2):S27-34. doi: 10.1097/rhu.0b013e31821d36f2. [PMID: 21654267]
  • Sophie L Stocker, Garry G Graham, Andrew J McLachlan, Kenneth M Williams, Richard O Day. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. The Journal of rheumatology. 2011 May; 38(5):904-10. doi: 10.3899/jrheum.101160. [PMID: 21285173]
  • Lisa K Stamp, John L O'Donnell, Mei Zhang, Jill James, Christopher Frampton, Murray L Barclay, Peter T Chapman. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis and rheumatism. 2011 Feb; 63(2):412-21. doi: 10.1002/art.30119. [PMID: 21279998]
  • Anne-Kathrin Tausche, Carsten Wunderlich, Martin Aringer. Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. Case reports in medicine. 2011; 2011(?):397646. doi: 10.1155/2011/397646. [PMID: 21629805]
  • Huiping Yuan, Xiaoyong Zhang, Xiuqing Huang, Yonggang Lu, Weiqing Tang, Yong Man, Shu Wang, Jianzhong Xi, Jian Li. NADPH oxidase 2-derived reactive oxygen species mediate FFAs-induced dysfunction and apoptosis of β-cells via JNK, p38 MAPK and p53 pathways. PloS one. 2010 Dec; 5(12):e15726. doi: 10.1371/journal.pone.0015726. [PMID: 21209957]
  • Theodora Szasz, A Elizabeth Linder, Robert P Davis, Robert Burnett, Gregory D Fink, Stephanie W Watts. Allopurinol does not decrease blood pressure or prevent the development of hypertension in the deoxycorticosterone acetate-salt rat model. Journal of cardiovascular pharmacology. 2010 Dec; 56(6):627-34. doi: 10.1097/fjc.0b013e3181f80194. [PMID: 20881613]
  • Mattheus K Reinders, Tim L Th A Jansen. New advances in the treatment of gout: review of pegloticase. Therapeutics and clinical risk management. 2010 Oct; 6(?):543-50. doi: 10.2147/tcrm.s6043. [PMID: 21127695]
  • Gamela Nasr, Cherine Maurice. Allopurinol and global left myocardial function in heart failure patients. Journal of cardiovascular disease research. 2010 Oct; 1(4):191-5. doi: 10.4103/0975-3583.74262. [PMID: 21264183]
  • Sophie L Stocker, Michael E Franklin, Jacqueline M Anderson, Peter I Pillans, Kenneth M Williams, Andrew J McLachlan, Richard O Day, Paul J Taylor. Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2010 Sep; 878(25):2363-8. doi: 10.1016/j.jchromb.2010.07.017. [PMID: 20702150]
  • Angelo L Gaffo, Kenneth G Saag. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core evidence. 2010 Jun; 4(?):25-36. doi: 10.2147/ce.s5999. [PMID: 20694062]
  • Xiaoli Wei, Wei Guo, Shuhong Wu, Li Wang, Peng Huang, Jinsong Liu, Bingliang Fang. Oxidative stress in NSC-741909-induced apoptosis of cancer cells. Journal of translational medicine. 2010 Apr; 8(?):37. doi: 10.1186/1479-5876-8-37. [PMID: 20398386]
  • Jun Fang, Takahiro Seki, Haibo Qin, Gahininath Y Bharate, Arun K Iyer, Hiroshi Maeda. Tissue protective effect of xanthine oxidase inhibitor, polymer conjugate of (styrene-maleic acid copolymer) and (4-amino-6-hydroxypyrazolo[3,4-d]pyrimidine), on hepatic ischemia-reperfusion injury. Experimental biology and medicine (Maywood, N.J.). 2010 Apr; 235(4):487-96. doi: 10.1258/ebm.2009.009304. [PMID: 20407081]
  • Yiling Fu, Rui Zhang, Deyin Lu, Haifeng Liu, Kiran Chandrashekar, Luis A Juncos, Ruisheng Liu. NOX2 is the primary source of angiotensin II-induced superoxide in the macula densa. American journal of physiology. Regulatory, integrative and comparative physiology. 2010 Mar; 298(3):R707-12. doi: 10.1152/ajpregu.00762.2009. [PMID: 20053956]
  • Lada Beara-Lasic, Michael H Pillinger, David S Goldfarb. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. International journal of nephrology and renovascular disease. 2010; 3(?):1-10. doi: 10.2147/ijnrd.s5563. [PMID: 21694922]
  • Zhen Tan, Tieying Dai, Xin Zhong, Ye Tian, Michelle K Leppo, Wei Dong Gao. Preservation of cardiac contractility after long-term therapy with oxypurinol in post-ischemic heart failure in mice. European journal of pharmacology. 2009 Oct; 621(1-3):71-7. doi: 10.1016/j.ejphar.2009.08.033. [PMID: 19737552]
  • Jasmin A Godbold, Rutger Rosenberg, Martin Solan. Species-specific traits rather than resource partitioning mediate diversity effects on resource use. PloS one. 2009 Oct; 4(10):e7423. doi: 10.1371/journal.pone.0007423. [PMID: 19829703]
  • Helen L Torrance, Manon J Benders, Jan B Derks, Carin M A Rademaker, Arie F Bos, Paul Van Den Berg, Mariangela Longini, Giuseppe Buonocore, MariaElena Venegas, Hernando Baquero, Gerard H A Visser, Frank Van Bel. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. Pediatrics. 2009 Jul; 124(1):350-7. doi: 10.1542/peds.2008-2228. [PMID: 19564319]
  • M K Reinders, C Haagsma, T L Th A Jansen, E N van Roon, J Delsing, M A F J van de Laar, J R B J Brouwers. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Annals of the rheumatic diseases. 2009 Jun; 68(6):892-7. doi: 10.1136/ard.2008.091462. [PMID: 18633127]
  • Stanislav Hason, Sona Stepankova, Alena Kourilova, Vladimir Vetterl, Jan Lata, Miroslav Fojta, Frantisek Jelen. Simultaneous electrochemical monitoring of metabolites related to the xanthine oxidase pathway using a grinded carbon electrode. Analytical chemistry. 2009 Jun; 81(11):4302-7. doi: 10.1021/ac900201g. [PMID: 19402672]
  • Seiji Nakamura, Toshinari Takamura, Naoto Matsuzawa-Nagata, Hiroaki Takayama, Hirofumi Misu, Hiroyo Noda, Satoko Nabemoto, Seiichiro Kurita, Tsuguhito Ota, Hitoshi Ando, Ken-Ichi Miyamoto, Shuichi Kaneko. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. The Journal of biological chemistry. 2009 May; 284(22):14809-18. doi: 10.1074/jbc.m901488200. [PMID: 19332540]
  • Jeannie Chao, Robert Terkeltaub. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Current rheumatology reports. 2009 Apr; 11(2):135-40. doi: 10.1007/s11926-009-0019-z. [PMID: 19296886]
  • Pietro Cirillo, Michael S Gersch, Wei Mu, Philip M Scherer, Kyung Mee Kim, Loreto Gesualdo, George N Henderson, Richard J Johnson, Yuri Y Sautin. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. Journal of the American Society of Nephrology : JASN. 2009 Mar; 20(3):545-53. doi: 10.1681/asn.2008060576. [PMID: 19158351]
  • David B Casey, Adeleke M Badejo, Jasdeep S Dhaliwal, Subramanyam N Murthy, Albert L Hyman, Bobby D Nossaman, Philip J Kadowitz. Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat. American journal of physiology. Heart and circulatory physiology. 2009 Feb; 296(2):H524-33. doi: 10.1152/ajpheart.00543.2008. [PMID: 19074675]
  • Y W Kim, B S Park, C H Ryu, S J Park, S W Kang, Y H Kim, I S Song, J H Shon. Allopurinol-induced aplastic anemia in a patient with chronic kidney disease. Clinical nephrology. 2009 Feb; 71(2):203-6. doi: 10.5414/cnp71203. [PMID: 19203517]
  • Melissa A Whidden, Joseph M McClung, Darin J Falk, Matthew B Hudson, Ashley J Smuder, W Bradley Nelson, Scott K Powers. Xanthine oxidase contributes to mechanical ventilation-induced diaphragmatic oxidative stress and contractile dysfunction. Journal of applied physiology (Bethesda, Md. : 1985). 2009 Feb; 106(2):385-94. doi: 10.1152/japplphysiol.91106.2008. [PMID: 18974366]
  • Robert Terkeltaub. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis research & therapy. 2009; 11(4):236. doi: 10.1186/ar2738. [PMID: 19664185]
  • Nader Nouri-Majalan, Ehsan Fotouhi Ardakani, Khalil Forouzannia, Hosein Moshtaghian. Effects of allopurinol and vitamin E on renal function in patients with cardiac coronary artery bypass grafts. Vascular health and risk management. 2009; 5(2):489-94. doi: 10.2147/vhrm.s5761. [PMID: 19554089]
  • A J van Dijk, N Parvizi, M A M Taverne, J Fink-Gremmels. Placental transfer and pharmacokinetics of allopurinol in late pregnant sows and their fetuses. Journal of veterinary pharmacology and therapeutics. 2008 Dec; 31(6):489-95. doi: 10.1111/j.1365-2885.2008.00976.x. [PMID: 19000269]
  • A A K El-Sheikh, J J M W van den Heuvel, J B Koenderink, F G M Russel. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. British journal of pharmacology. 2008 Dec; 155(7):1066-75. doi: 10.1038/bjp.2008.343. [PMID: 18724382]
  • Miao Hu, Brian Tomlinson. Febuxostat in the management of hyperuricemia and chronic gout: a review. Therapeutics and clinical risk management. 2008 Dec; 4(6):1209-20. doi: 10.2147/tcrm.s3310. [PMID: 19337428]
  • Joshua M Hare, Brian Mangal, Joanne Brown, Charles Fisher, Ronald Freudenberger, Wilson S Colucci, Douglas L Mann, Peter Liu, Michael M Givertz, Richard P Schwarz. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. Journal of the American College of Cardiology. 2008 Jun; 51(24):2301-9. doi: 10.1016/j.jacc.2008.01.068. [PMID: 18549913]
  • Taku Inokuchi, Tuneyoshi Ka, Asako Yamamoto, Sumio Takahashi, Zenta Tsutsumi, Yuji Moriwaki, Tetsuya Yamamoto. Effects of allopurinol on beer-induced increases in plasma concentrations of purine bases and uridine. Nucleosides, nucleotides & nucleic acids. 2008 Jun; 27(6):601-3. doi: 10.1080/15257770802138392. [PMID: 18600512]
  • Günnur Koçer, Umit Kemal Sentürk, Oktay Kuru, Filiz Gündüz. Potential sources of oxidative stress that induce postexercise proteinuria in rats. Journal of applied physiology (Bethesda, Md. : 1985). 2008 Apr; 104(4):1063-8. doi: 10.1152/japplphysiol.00581.2007. [PMID: 18258803]
  • Yewon Chung, Sophie L Stocker, Garry G Graham, Richard O Day. Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy. The American journal of the medical sciences. 2008 Mar; 335(3):219-26. doi: 10.1097/maj.0b013e31815acb10. [PMID: 18344696]
  • Duangchit Panomvana, Siriluk Sripradit, Sungchai Angthararak. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2008 Feb; 14(1):6-11. doi: 10.1097/rhu.0b013e318164dceb. [PMID: 18431090]
  • Iwao Ohno, Hideaki Okabe, Yuichiro Yamaguchi, Hajime Saikawa, Daijiro Uetake, Miho Hikita, Hideho Gomi, Kimiyoshi Ichida, Tatsuo Hosoya. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol]. Nihon Jinzo Gakkai shi. 2008; 50(4):506-12. doi: . [PMID: 18546882]
  • Sophie L Stocker, Kenneth M Williams, Andrew J McLachlan, Garry G Graham, Richard O Day. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clinical pharmacokinetics. 2008; 47(2):111-8. doi: 10.2165/00003088-200847020-00004. [PMID: 18193917]
  • N C den Hollander, D J Mulder, R Graaff, S R Thorpe, J W Baynes, G P A Smit, A J Smit. Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia. Journal of inherited metabolic disease. 2007 Nov; 30(6):916-23. doi: 10.1007/s10545-007-0507-0. [PMID: 17570077]
  • Mattheus K Reinders, Lars C Nijdam, Eric N van Roon, Kris L L Movig, Tim L Th A Jansen, Mart A F J van de Laar, Jacobus R B J Brouwers. A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection. Journal of pharmaceutical and biomedical analysis. 2007 Oct; 45(2):312-7. doi: 10.1016/j.jpba.2007.08.002. [PMID: 17890037]
  • André Dejam, Christian J Hunter, Carole Tremonti, Ryszard M Pluta, Yuen Yi Hon, George Grimes, Kristine Partovi, Mildred M Pelletier, Edward H Oldfield, Richard O Cannon, Alan N Schechter, Mark T Gladwin. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation. 2007 Oct; 116(16):1821-31. doi: 10.1161/circulationaha.107.712133. [PMID: 17893272]
  • Dorit Knappe, Bjoern Sill, Bjoern Tharun, Ralf Koester, Stephan Baldus, Thomas Muenzel, Thomas Meinertz, Jan Kähler. Endothelin-1 in humans is increased by oxygen-derived radicals ex vivo and in vivo. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2007 Sep; 55(6):306-14. doi: 10.2310/6650.2007.00013. [PMID: 17963680]
  • Nicola Dalbeth, Lisa Stamp. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Seminars in dialysis. 2007 Sep; 20(5):391-5. doi: 10.1111/j.1525-139x.2007.00270.x. [PMID: 17897242]
  • Sukirti Kalra, Gopabandhu Jena, Kulbhushan Tikoo, Anup Kumar Mukhopadhyay. Preferential inhibition of xanthine oxidase by 2-amino-6-hydroxy-8-mercaptopurine and 2-amino-6-purine thiol. BMC biochemistry. 2007 May; 8(?):8. doi: 10.1186/1471-2091-8-8. [PMID: 17511860]
  • Jan T Kielstein, Alexander Woywodt, Shelley R Salpeter. Letter by Kielstein et al regarding article, 'High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid'. Circulation. 2007 May; 115(18):e450-1; author reply e451. doi: 10.1161/circulationaha.106.683831. [PMID: 17485587]
  • Peter G Osborne, Masaaki Hashimoto. Brain ECF antioxidant interactions in hamsters during arousal from hibernation. Behavioural brain research. 2007 Mar; 178(1):115-22. doi: 10.1016/j.bbr.2006.12.006. [PMID: 17207864]
  • Lisa Cammalleri, Mariano Malaguarnera. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. International journal of medical sciences. 2007 Mar; 4(2):83-93. doi: 10.7150/ijms.4.83. [PMID: 17396159]
  • Rebecca Widmer, Martina Engels, Peter Voss, Tilman Grune. Postanoxic damage of microglial cells is mediated by xanthine oxidase and cyclooxygenase. Free radical research. 2007 Feb; 41(2):145-52. doi: 10.1080/10715760600978807. [PMID: 17364940]
  • Eiji Warabi, Wakako Takabe, Takashi Minami, Kenji Inoue, Ken Itoh, Masayuki Yamamoto, Tetsuro Ishii, Tatsuhiko Kodama, Noriko Noguchi. Shear stress stabilizes NF-E2-related factor 2 and induces antioxidant genes in endothelial cells: role of reactive oxygen/nitrogen species. Free radical biology & medicine. 2007 Jan; 42(2):260-9. doi: 10.1016/j.freeradbiomed.2006.10.043. [PMID: 17189831]
  • Richard O Day, Garry G Graham, Mark Hicks, Andrew J McLachlan, Sophie L Stocker, Kenneth M Williams. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clinical pharmacokinetics. 2007; 46(8):623-44. doi: 10.2165/00003088-200746080-00001. [PMID: 17655371]
  • Stephan Baldus, Kai Müllerleile, Phil Chumley, Daniel Steven, Volker Rudolph, Gunnar K Lund, Hans-Jürgen Staude, Alexander Stork, Ralf Köster, Jan Kähler, Christian Weiss, Thomas Münzel, Thomas Meinertz, Bruce A Freeman, Thomas Heitzer. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free radical biology & medicine. 2006 Oct; 41(8):1282-8. doi: 10.1016/j.freeradbiomed.2006.07.010. [PMID: 17015175]
  • V G Ladygin, G N Shirshikova. [The current concepts of functional role of carotenoids in the eukaryotic chloroplasts]. Zhurnal obshchei biologii. 2006 May; 67(3):163-89. doi: . [PMID: 16862869]
  • Oscar A Bizzozero, Jennifer L Ziegler, Gisela De Jesus, Federico Bolognani. Acute depletion of reduced glutathione causes extensive carbonylation of rat brain proteins. Journal of neuroscience research. 2006 Mar; 83(4):656-67. doi: 10.1002/jnr.20771. [PMID: 16447283]
  • T Ka, Y Moriwaki, T Inokuchi, A Yamamoto, S Takahashi, Z Tsutsumi, T Yamamoto. Effects of allopurinol on beer-induced increases in plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine). Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2006 Mar; 38(3):188-92. doi: 10.1055/s-2006-925429. [PMID: 16673211]
  • Elena Daghini, Alejandro R Chade, James D Krier, Daniele Versari, Amir Lerman, Lilach O Lerman. Acute inhibition of the endogenous xanthine oxidase improves renal hemodynamics in hypercholesterolemic pigs. American journal of physiology. Regulatory, integrative and comparative physiology. 2006 Mar; 290(3):R609-15. doi: 10.1152/ajpregu.00436.2005. [PMID: 16284087]
  • Robert Terkeltaub, David A Bushinsky, Michael A Becker. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis research & therapy. 2006; 8 Suppl 1(?):S4. doi: 10.1186/ar1909. [PMID: 16820043]
  • Mitsuharu Kaya, Yuji Moriwaki, Tuneyoshi Ka, Taku Inokuchi, Asako Yamamoto, Sumio Takahashi, Zenta Tsutsumi, Junzou Tsuzita, Yoshitaka Oku, Tetsuya Yamamoto. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise. Metabolism: clinical and experimental. 2006 Jan; 55(1):103-7. doi: 10.1016/j.metabol.2005.07.013. [PMID: 16324927]
  • George Nuki, Peter A Simkin. A concise history of gout and hyperuricemia and their treatment. Arthritis research & therapy. 2006; 8 Suppl 1(?):S1. doi: 10.1186/ar1906. [PMID: 16820040]
  • C Felici, I Ciari, L Terzuoli, B Porcelli, C Setacci, M Giubbolini, E Marinello. Purine catabolism in advanced carotid artery plaque. Nucleosides, nucleotides & nucleic acids. 2006; 25(9-11):1291-4. doi: 10.1080/15257770600890772. [PMID: 17065109]
  • Takashi Iwanaga, Daisuke Kobayashi, Masamichi Hirayama, Tomoji Maeda, Ikumi Tamai. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug metabolism and disposition: the biological fate of chemicals. 2005 Dec; 33(12):1791-5. doi: 10.1124/dmd.105.006056. [PMID: 16135657]
  • Stephan Baldus, Ralf Köster, Phillip Chumley, Thomas Heitzer, Volker Rudolph, Mir Abolfazl Ostad, Ascan Warnholtz, Hans-Jürgen Staude, Felix Thuneke, Klaus Koss, Jürgen Berger, Thomas Meinertz, Bruce A Freeman, Thomas Münzel. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free radical biology & medicine. 2005 Nov; 39(9):1184-90. doi: 10.1016/j.freeradbiomed.2005.06.004. [PMID: 16214034]
  • Ariel J Reyes, William P Leary. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?. Cardiovascular drugs and therapy. 2005 Oct; 19(5):311-3. doi: 10.1007/s10557-005-4971-1. [PMID: 16382292]
  • M Takada, H Okada, T Kotake, N Kawato, M Saito, M Nakai, T Gunji, M Shibakawa. Appropriate dosing regimen of allopurinol in Japanese patients. Journal of clinical pharmacy and therapeutics. 2005 Aug; 30(4):407-12. doi: 10.1111/j.1365-2710.2005.00670.x. [PMID: 15985055]
  • Panayiota Karatza, Stathis Frillingos. Cloning and functional characterization of two bacterial members of the NAT/NCS2 family in Escherichia coli. Molecular membrane biology. 2005 May; 22(3):251-61. doi: 10.1080/09687860500092927. [PMID: 16096267]